RAD-150, also sold as TLB-150, is the benzoate ester of the experimental SARM RAD-140 (Testolone). SARMs (selective androgen receptor modulators) are non-steroidal molecules that activate the androgen receptor, the same receptor testosterone acts on. RAD-150 is RAD-140 with a benzoic acid group attached through an ester bond. The structure appears in a Radius Health patent on SARMs, where it is one of many listed compounds.
The most important fact: no published study has tested RAD-150 in people or animals. We found no peer-reviewed paper on it in PubMed. The only measured data point is a single in vitro (test-tube) binding value from the patent. In that assay RAD-150 bound the androgen receptor about 65 times more weakly than RAD-140. There is no published data on its half-life, its effects on muscle, or its safety. It is not approved for any use.
This page summarizes what the chemical databases, the patent record and regulators report, and what is known about the parent compound. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Experimental non-steroidal SARM; benzoate ester of RAD-140 |
| Other names | TLB-150; TLB 150 benzoate; RAD150; CAS 1208070-53-4 |
| Formula and weight | C₂₇H₂₀ClN₅O₃, 497.9 g/mol (RAD-140: 393.8 g/mol) |
| Origin | Listed in US Patent 8,629,167 (Radius Health; priority 2008, granted 2014) |
| Doses studied in people | None |
| Half-life | Unknown; no pharmacokinetic study has been published |
| Androgen receptor binding | IC50 130 nM vs 2 nM for RAD-140 in the same patent assay (rat receptor, in vitro) |
| FDA status | Not approved for any use; FDA calls products marketed as SARMs unapproved drugs |
| US controlled-substance status | Not on the DEA controlled substances list (August 2026 edition) |
| WADA status | Prohibited at all times as a SARM under S1.2 (class covered; not named) |
What it is
PubChem lists RAD-150 under the synonyms “RAD150,” “TLB 150 Benzoate” and CAS number 1208070-53-4 (PubChem CID 68547459). Its chemical name is [(1R,2S)-1-(3-chloro-4-cyano-2-methylanilino)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]propan-2-yl] benzoate.
Comparing the two structures in PubChem shows exactly how it differs from RAD-140 (PubChem CID 44200882):
| Feature | RAD-140 | RAD-150 |
|---|---|---|
| Formula | C₂₀H₁₆ClN₅O₂ | C₂₇H₂₀ClN₅O₃ |
| Molecular weight | 393.8 g/mol | 497.9 g/mol |
| Side chain | Free hydroxyl (-OH) group on the propyl side chain | Same position capped with a benzoate ester |
| Core structure and stereochemistry | (1R,2S); oxadiazole ring with two benzonitrile groups | Identical |
| Computed lipophilicity (XLogP3) | 3.1 | 5.4 |
Everything else in the molecule is the same. Like RAD-140, it has no steroid skeleton. The higher computed XLogP3 is an estimate, not a measurement; it means the ester is predicted to be much more fat-soluble.
By weight, RAD-140 makes up about 79% of the ester (393.8 ÷ 497.9). This is the same arithmetic used for testosterone esters. It would only matter if the body fully cleaved the ester back to RAD-140, and no study has shown that it does.
Where it comes from
The compound appears in US Patent 8,629,167, “Selective androgen receptor modulators,” assigned to Radius Health with Chris P. Miller as inventor. The patent family has a priority date of February 22, 2008, and this patent was granted on January 14, 2014 (PubChem patent record). PubChem links RAD-150 to this patent as compound 87. The patent covers a large family of SARMs and methods of treating conditions such as sarcopenia (age-related muscle loss) and prostate cancer.
RAD-140 itself was the compound Radius chose to develop and publish (Miller et al., ACS Med Chem Lett 2011). We found no publication or trial registration showing that Radius or anyone else developed RAD-150 as a drug candidate.
How it works in the body
Receptor binding: the only measured data
The patent reports an androgen receptor binding assay for its compounds. PubChem holds these results as a BindingDB-curated dataset, measured against the rat androgen receptor (PubChem AID 1800312; UniProt P15207). IC50 is the concentration needed to displace half of a labeled reference ligand; lower means tighter binding.
| Compound | AR binding IC50 (same assay) |
|---|---|
| RAD-140 | 2 nM |
| RAD-150 | 130 nM |
In this assay the ester bound about 65-fold less tightly than RAD-140. Miller et al. reported a Ki (a related binding constant) of 7 nM for RAD-140 in their 2011 paper, using a commercial fluorescence-based assay. Values from different reports are not directly comparable, so the side-by-side numbers above, from one assay, are the fairer comparison.
A weaker in vitro binding value for an ester is not surprising. It does not show how RAD-150 behaves in a living body, where enzymes called esterases might cut the ester off and release RAD-140. Whether that happens, how fast, and how much of a dose reaches the blood as RAD-140 have never been published.
Pharmacokinetics
No pharmacokinetic study of RAD-150 exists in people or animals. Its half-life, oral bioavailability (the share of a dose that reaches the blood) and metabolites are unknown.
For comparison, the parent compound has some data. In a phase 1 trial of RAD-140 in 22 women with metastatic breast cancer, the half-life was 44.7 hours (LoRusso et al., Clin Breast Cancer 2022). That figure belongs to RAD-140 and cannot be transferred to the ester.
About “longer-acting” and “improved RAD-140” claims. RAD-150 is often marketed as a more stable or longer-lasting version of RAD-140, by analogy with testosterone esters. We found no published data to support this. The only measured comparison is the binding assay above, where the ester was weaker. Testosterone esters work as slow-release depots because they are injected in oil; RAD-150 has no studied formulation, and no study has measured how fast it is cleared.
Regulatory status
- FDA. RAD-150 is not approved for any use. FDA states that products sold as SARMs “have not been approved by the FDA” and that they are unapproved drugs rather than dietary supplements. FDA notes that such products are sometimes labeled “for research purposes” or “not for human consumption” while being sold directly to consumers with dosing instructions (FDA, 2025). FDA warning letters to online sellers have named the parent compound, RAD-140, as an unapproved new drug (FDA warning letter, 2025). We did not find a warning letter that names RAD-150.
- DEA. Neither RAD-150 nor RAD-140 appears on the DEA’s alphabetical list of controlled substances (DEA, August 2026). That means it is not a scheduled drug; it does not make sales legal.
- WADA. The 2026 Prohibited List bans “selective androgen receptor modulators” under S1.2 “Other anabolic agents,” at all times. The list says “including, but not limited to,” and names RAD140 among its examples (WADA 2026 Prohibited List). RAD-150 is not named, but as a SARM it falls within the class.
What the research shows
There is no research on RAD-150’s effects. Specifically, no published study has measured any of the following:
- muscle, strength or body composition, in people or animals;
- effects on testosterone, LH, FSH, sperm production, lipids or the liver;
- tissue selectivity (muscle vs prostate);
- toxicity or a safe dose.
Any claim about what RAD-150 does in the body, including dose figures, comes from outside the scientific literature. For the evidence on the parent compound, which is itself limited to animal studies and one small cancer trial, see RAD-140.
Side effects and risks
Unknown, with RAD-140 as the closest guide
No safety data exist for RAD-150. If the ester is converted to RAD-140 in the body, RAD-140’s risks would be expected to apply. Those include liver injury: in the RAD-140 phase 1 trial, raised AST and ALT (liver enzymes) were the most common adverse events, at 59.1% and 45.5% of patients, and grade 3 or 4 AST/ALT elevations occurred in 22.7% (LoRusso et al., 2022). Case reports of cholestatic liver injury in recreational RAD-140 users are summarized on the RAD-140 page.
FDA lists the following potential harms for SARMs as a group (FDA, 2025):
- liver injury and acute liver failure, including cases needing hospitalization;
- increased risk of heart attack or stroke;
- psychosis or hallucinations, and sleep disturbances;
- sexual dysfunction, infertility and testicular shrinkage;
- pregnancy miscarriage.
Hormonal suppression
Whether RAD-150 suppresses natural testosterone production has never been tested. The RAD-140 trial showed clear androgen activity in people: SHBG fell in 18 of 18 women and PSA rose in 16 of 20. Claims that a SARM “doesn’t suppress” are untested for RAD-150, not proven.
Who should not use it
RAD-150 is an unstudied research chemical with no established safe dose for any purpose. Athletes subject to anti-doping rules also risk a violation, since SARMs are banned in and out of competition.
Quality and contamination
Products sold online as SARMs are not made under drug manufacturing standards, and their labels are often wrong. A JAMA study bought 44 products marketed as SARMs from internet sellers (Van Wagoner et al., JAMA 2017):
| Finding | Products |
|---|---|
| Contained at least one SARM | 23 of 44 (52%) |
| Contained another unapproved drug (e.g. ibutamoren, GW501516, SR9009) | 17 (39%) |
| No active compound detected | 4 (9%) |
| Contained substances not on the label | 11 (25%) |
| Amount matched the label | 18 (41%) |
That study did not test RAD-150. Because no published analytical method or reference study exists for it, buyers have no independent way to know whether a “RAD-150” product contains the ester, RAD-140, another drug, or nothing. Related pages: RAD-140, Ostarine, Ligandrol.
Key takeaways
- A benzoate ester of RAD-140. Same core molecule with a benzoate group on the side-chain hydroxyl; RAD-140 is about 79% of its weight.
- No published studies. No human, animal or pharmacokinetic study of RAD-150 has been published; its half-life, effects and safety are unknown.
- Weaker binding in the one test. In the patent’s in vitro assay it bound the androgen receptor about 65-fold more weakly than RAD-140 (130 vs 2 nM).
- “Longer-acting RAD-140” is unproven. No data show that the ester lasts longer, works better or is converted to RAD-140 in the body.
- Unapproved and banned in sport. FDA treats products sold as SARMs as unapproved drugs, and WADA bans all SARMs at all times.
- Parent-compound risks are the best guide. RAD-140 has caused liver enzyme rises in trial patients and cholestatic liver injury in recreational users.
Sources
- National Center for Biotechnology Information. PubChem compound summary for CID 68547459, RAD150 (TLB 150 benzoate). PubChem.
- National Center for Biotechnology Information. PubChem compound summary for CID 44200882, RAD140 (vosilasarm). PubChem.
- Miller CP, inventor; Radius Health Inc, assignee. Selective androgen receptor modulators. US Patent 8,629,167 B2. Granted January 14, 2014. PubChem.
- National Center for Biotechnology Information. PubChem BioAssay AID 1800312: Biological assay from US Patent US8629167, “Selective androgen receptor modulators” (BindingDB). PubChem.
- UniProt Consortium. P15207, androgen receptor (Rattus norvegicus). UniProt.
- Miller CP, Shomali M, Lyttle CR, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett. 2011;2(2):124–129. PubMed.
- LoRusso P, Hamilton E, Ma C, et al. A first-in-human phase 1 study of a novel selective androgen receptor modulator (SARM), RAD140, in ER+/HER2- metastatic breast cancer. Clin Breast Cancer. 2022;22(1):67–77. PubMed.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010. PubMed.
- Food and Drug Administration. Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more. Content current as of December 2, 2025. FDA.
- Food and Drug Administration. Warning letter to Atomix LLC, MARCS-CMS 719111. December 12, 2025. FDA.
- Drug Enforcement Administration, Diversion Control Division. Controlled substances, alphabetical order. August 27, 2026. DEA.
- World Anti-Doping Agency. The 2026 Prohibited List: International Standard. Effective January 1, 2026. WADA.